Litronesib-LY-2523355-DataSheet-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemELitronesibCat. No.: HY-14846CAS No.: 910634-41-2Synonyms: LY-2523355; KF-89617分式: CHNOS分量: 511.7作靶點(diǎn): Kinesin作通路: Cell Cycle/DNA Damage; Cytoskeleton儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn)

2、DMSO : 50 mg/mL (97.71 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 1.9543 mL 9.7713 mL 19.5427 mL5 mM 0.3909 mL 1.9543 mL 3.9085 mL10 mM 0.1954 mL 0.9771 mL 1.9543 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)注意儲(chǔ)備液的保存式和期限。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥式選擇適當(dāng)?shù)娜芙獍?，配制前?qǐng)先配制澄清的儲(chǔ)備液，

3、再依次添加助溶劑(為保證實(shí)驗(yàn)結(jié)果的可靠性，體內(nèi)實(shí)驗(yàn)的作液，建議您現(xiàn)現(xiàn)配，當(dāng)天使；澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占)：1. 請(qǐng)依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (4.89 mM); Clear solution2. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (4.89 mM); Clear solution1/3 Master of

4、Small Molecules 您邊的抑制劑師www.MedChemE3. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (4.89 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 Litronesib種選擇性的有絲分裂特異性運(yùn)動(dòng)蛋 Eg5 抑制劑，具有抗腫瘤的活性。IC50 & Target Eg5體外研究 Litronesib (LY2523355) is a selective Eg5 inhibitor. Litronesib (25 nM) induces cancer cells to

5、 death duringmitotic arrest, and this needs sustained activation of spindle-assembly checkpoint (SAC) 1.體內(nèi)研究 Litronesib (LY2523355; 1.1, 3.3, 10, and 30 mg/kg, i.v.) shows antitumor activity in a dose-dependently, andcauses a dramatic increase in cancer cells immuno-positive for histone H3 phosphory

6、lation in Colo205xenograft tumors 1.PROTOCOLCell Assay 1 Cancer cells are plated in poly-d-lysine coated 96-well plates and incubated overnight. Cells are then treatedwith indicated concentrations of Litronesib for various time periods. Cells are then fixed with 3.7%formaldehyde in PBS for 45 minute

7、s or 1 Prefer fixative solution for 30 minutes, at room temperature, andpermeabilized with cold methanol for 10 minutes and then 0.2% Triton X-100 in PBS for 10 minutes. Cellsare washed three times with PBS. Cells are then incubated with 100 g/mL DNase-free RNase and 10 g/mLof propidium iodide for 1

8、 hour and scanned for mitotic index (MI) measurement based on DNA condensationas percentage of cells with condensed DNA. For MI based on histone H3 phosphorylation or apoptosisanalysis, cells are incubated overnight at 4C with anti-phospho-histone H3 antibody or anti-phospho-histoneH2AX at 1:1,000 d

9、ilution with 5% bovine serum albumin (BSA) in PBS, respectively. Cells are washed threetimes with 0.2% Triton-X 100 in PBS and incubated with Alexa 488 secondary antibody (1:1,000 in PBS-2%BSA) for 60 minutes at room temperature. Cells are washed three times again with PBS and stained for 15minutes

10、in PBS containing 10 g/mL propidium iodide and 100 g/mL RNaseA. The stained cells arescanned with an Acumen Explorer eX3 microplate cytometer. The results are expressed as percentage ofcells positive for phospho-histone H3-Ser10 or phospho-histone H2AX 1.MCE has not independently confirmed the accur

11、acy of these methods. They are for reference only.Animal Primary human-tumor xenograft models are established and maintained in nude mice. Antitumor efficacy inAdministration 1 subcutaneous xenograft tumor-bearing mice with 10 mice per treatment group from either established cancercell lines or frag

12、ments of human tumor explants is evaluated as tumor volume by serial calipermeasurements and is calculated. The p388 syngeneic tumor model is developed for high-content imaginganalysis using female BDF1 mice, weighing 20 to 23 g, which are acclimated in-house for one week beforetheir use in experime

13、nts. p388 murine lymphocytic leukemia cells are authenticated by STR assay andmaintained in RPMI1640 medium containing 10% FBS. For inoculation, the cells are washed with serum-freemedium three times and 1.25 million cells are implanted by intraperitoneal injection into mice. On day 5 after2/3 Maste

14、r of Small Molecules 您邊的抑制劑師www.MedChemEimplantation, mice are treated with Litronesib, via either intravenous bolus or intravenous infusion atappropriate doses and durations. Mice are euthanized and the ascitic (intraperitoneal) fluid containing thep388 tumor cells is drawn and analyzed by acumen,

15、flow cytometry, and TUNEL assays for phospho-histoneH3, G2-M, and apoptosis. For pharmacokinetic study, the blood samples are collected via cardiac punctureand generated plasma with EDTA and determined Litronesib exposure in the plasma 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Ye XS, et al. A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent AntitumorActivity in Xenograft Tumor Models. Mol C